Genzyme

Xenon appoints Bridger as executive vice president, R&D

Thursday, February 14, 2013 08:00 AM

Xenon Pharmaceuticals, a clinical genetics-based drug discovery and development company focused on rare diseases, has appointed Gary J. Bridger, PhD, as executive vice president of research and development.

More... »

CEO of Sanofi designated as new president elect of EFPIA

Wednesday, November 7, 2012 01:55 PM

The European Federation of Pharmaceutical Industries and Associations (EFPIA), which represents the pharmaceutical industry operating in Europe, has designated Christopher A. Viehbacher, CEO of Sanofi, as the new president elect of EFPIA. He will take up the position as of June 2013 for a two year term.

More... »

Alnylam, Genzyme to develop and commercialize RNAi therapeutics in Asia

Monday, October 22, 2012 12:01 PM

Alnylam Pharmaceuticals, a biopharmaceutical company based in Cambridge, Mass., and Genzyme, a Sanofi company, have formed an exclusive alliance to develop and commercialize RNAi therapeutics targeting transthyretin (TTR) for the treatment of transthyretin-mediated amyloidosis (ATTR) in Japan and other Asia-Pacific countries.

More... »

DART Therapeutics appoints executive team

Friday, September 14, 2012 01:51 PM

DART Therapeutics, a Cambridge, Mass.-based new-model biotechnology firm focused on developing therapies for Duchenne Muscular Dystrophy (DMD), has appointed an executive team. Members include co-founder and executive chairman Eugene W. Williams with the new title of CEO, Ernest D. Bush, PhD, as chief scientific officer., Dr. Elliot Goldstein as chief medical officer, and Cabot Brown as chief financial officer.

More... »

Zyngenia appoints Frank Hsu as chief medical officer

Thursday, May 31, 2012 02:10 PM

Zyngenia, a Gaithersburg, Md.-based biopharmaceutical company developing next-generation multi-specific antibody-based drugs, has appointed Frank Hsu, M.D., as chief medical officer and a member of its executive team.

More... »

Report: Orphan drug market on the rise

Thursday, May 24, 2012 09:00 AM

GBI Research, a pharmaceutical market expert, has released its report "Orphan Disease Therapeutics Market to 2018: Improved Understanding of Rare Diseases' Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation,” which provides insights into the orphan disease therapeutics market until 2018.

More... »

Genzyme announces FDA approval of Framingham manufacturing plant

Tuesday, January 24, 2012 02:52 PM

Cambridge, Mass.-based Genzyme, a Sanofi company, said the FDA has approved its manufacturing plant in Framingham, Mass., for the production of Fabrazyme (agalsidase beta). This follows the previously announced approval by the EMA last week.

More... »

Genzyme, Cystic Fibrosis Foundation Therapeutics ink research agreement

Wednesday, November 16, 2011 02:33 PM

Genzyme, a Sanofi company, and Cystic Fibrosis Foundation Therapeutics, the nonprofit affiliate of the Cystic Fibrosis Foundation, have signed a research agreement to support the discovery of new drugs to treat people with the most common mutation found in patients with CF, Delta F508.

More... »

NanoString raises $20 million in Series D financing

Monday, November 7, 2011 09:52 AM

NanoString Technologies, a privately held provider of life science tools for translational research and developer of molecular diagnostics, has closed $20 million in a Series D round of equity financing. New investors include GE, BioMed Ventures and Henri Termeer, former chairman and CEO of Genzyme. All previous venture investors in NanoString also participated in the financing, including Clarus Ventures, Draper Fisher Jurvetson and OVP Venture Partners.

More... »

Sanofi restructues cutting sales jobs

Wednesday, November 2, 2011 01:43 PM

French drugmaker Sanofi has reported it is reorganizing research operations in the U.S. and planning to trim its sales force for the second time in barely a year as it aims to boost efficiency, according to the Associated Press.

More... »